- Home
- APLM vs ISPO Comparison
APLM vs ISPO Comparison
Compare APLM & ISPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- ISPO
- Stock Information
- Founded
- APLM 2016
- ISPO 2010
- Country
- APLM United States
- ISPO United States
- Employees
- APLM N/A
- ISPO N/A
- Industry
- APLM Blank Checks
- ISPO Blank Checks
- Sector
- APLM Finance
- ISPO Finance
- Exchange
- APLM Nasdaq
- ISPO Nasdaq
- Market Cap
- APLM 15.6M
- ISPO 13.4M
- IPO Year
- APLM N/A
- ISPO N/A
- Fundamental
- Price
- APLM $0.16
- ISPO $3.85
- Analyst Decision
- APLM Strong Buy
- ISPO Buy
- Analyst Count
- APLM 2
- ISPO 2
- Target Price
- APLM $4.25
- ISPO $10.50
- AVG Volume (30 Days)
- APLM 934.3K
- ISPO 35.6K
- Earning Date
- APLM 08-14-2024
- ISPO 11-04-2024
- Dividend Yield
- APLM N/A
- ISPO N/A
- EPS Growth
- APLM N/A
- ISPO N/A
- EPS
- APLM N/A
- ISPO N/A
- Revenue
- APLM $2,101,000.00
- ISPO $300,935,000.00
- Revenue This Year
- APLM N/A
- ISPO N/A
- Revenue Next Year
- APLM N/A
- ISPO N/A
- P/E Ratio
- APLM N/A
- ISPO N/A
- Revenue Growth
- APLM 70.54
- ISPO N/A
- 52 Week Low
- APLM $0.11
- ISPO $3.11
- 52 Week High
- APLM $3.18
- ISPO $9.98
- Technical
- Relative Strength Index (RSI)
- APLM 60.35
- ISPO 43.72
- Support Level
- APLM $0.13
- ISPO $3.65
- Resistance Level
- APLM $0.18
- ISPO $4.07
- Average True Range (ATR)
- APLM 0.01
- ISPO 0.30
- MACD
- APLM 0.00
- ISPO -0.06
- Stochastic Oscillator
- APLM 65.52
- ISPO 16.20
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About ISPO Inspirato Incorporated
Inspirato Inc is a luxury travel subscription luxury travel company that provides exclusive access to a managed and controlled portfolio of curated vacation options, delivered through a model designed to ensure the service, certainty, and value that discerning customers demand. The Inspirato portfolio includes branded luxury vacation homes, accommodations at five-star hotel and resort partners, and custom travel experiences. It has a geographic location in the United States and Outside the United States. It generates the majority of its revenue from the United States.